Skip to main content
. 2020 Dec 15;10(8):e254. doi: 10.1002/ctm2.254

FIGURE 6.

FIGURE 6

An overview of the workflow and the major conclusions in this study. Through tracking the serial changes of plasma ctDNA from GC patients underwent HER2‐targeted therapy or immunotherapy, our work provided four section of clues that directed the clinical decision‐making of GC